AGM Statement

AI SummaryClose X

Thalia Therapeutics plc provided an AGM statement highlighting a significant period of evolution following its strategic repositioning as an RNA therapeutics company. The proposed acquisition of Sanmirna Therapeutics and an associated £2.75 million oversubscribed fundraise are described as transformational steps, accelerating the company's transition to a clinical-stage entity and strengthening its RNA therapeutics pipeline. This acquisition will add miRisten, a Phase 1 clinical-stage microRNA therapeutic for Acute Myeloid Leukaemia, alongside the proprietary Nuvec® delivery technology and a cardiovascular siRNA program, creating a diversified portfolio targeting oncology and cardiovascular disease. With funding secured for planned work streams, including the completion of the Phase 1 miRisten clinical trial, with topline data expected in the first half of 2027, the company is focused on integrating Sanmirna, advancing its cardiovascular program, and developing Nuvec®.

Disclaimer*

UK 100

Latest directors dealings